Literature DB >> 15924252

Mutations of the PIK3CA gene are rare in human glioblastoma.

Wolf Mueller, Masahiro Mizoguchi, Erica Silen, Katrina D'Amore, Catherine L Nutt, David N Louis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15924252     DOI： 10.1007/s00401-005-1001-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  9 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Authors:  Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

Review 4.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

Review 5.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

6.  MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Authors:  Junchao Cai; JingJing Zhao; Nu Zhang; Xiaonan Xu; Rong Li; Yang Yi; Lishan Fang; Le Zhang; Mengfeng Li; Jueheng Wu; Heng Zhang
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

7.  Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.

Authors:  Katrin Höland; Danielle Boller; Christian Hagel; Silvia Dolski; András Treszl; Olivier E Pardo; Paulina Cwiek; Fabiana Salm; Zaira Leni; Peter R Shepherd; Beata Styp-Rekowska; Valentin Djonov; André O von Bueren; Karl Frei; Alexandre Arcaro
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

Review 8.  Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.

Authors:  Amir Barzegar Behrooz; Zahra Talaie; Fatemeh Jusheghani; Marek J Łos; Thomas Klonisch; Saeid Ghavami
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

9.  Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.

Authors:  Asneha Iqbal; Frank Eckerdt; Jonathan Bell; Ichiro Nakano; Francis J Giles; Shi-Yuan Cheng; Rishi R Lulla; Stewart Goldman; Leonidas C Platanias
Journal:  Oncotarget       Date:  2016-05-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.